| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Aclarion, Inc. Common Stock$3.12
+0.01 (+0.32%)
F 13Pipeline Score Tools & Services · Clinical
Market Cap
7.37 M
EPS
-17.21
P/E Ratio
-0.19 $
Value Trade
190.92 K
SEC Financials
Q1 2026Dilution Risk
Revenue
21.14 K
R&D Expenses
315.42 K
Operating CF
-2.64 M
Total Assets
20.64 M
Total Liabilities
986.21 K
Equity
19.65 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
19.00 M
Monthly Burn
881.00 K
Runway
20.5 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
38.36 K
52 Week Range
2.34 - 12.03
% held by Insiders
10.56 %
% held by Institutions
4.57 %
Enterprise Value
-4.67 M
Total Shares
2.46 M
Short %
8.19 %
Float Shares
2.42 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F13
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 10%
Micro Cap (rank 815 of 905)
Percentile RankAclarion, Inc. Common Stock has significant pipeline risk (13/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ACON
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Aclarion, Inc. Common Stock (ACON) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ACON
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ACON
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ACON
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ACON Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ACON Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ACON
Jun 10, 2026Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub
Aclarion, Inc. will present at the Planet MicroCap Las Vegas 2026 on June 17, 2026. The company is experiencing significant growth in its Nociscan platform, which aids in diagnosing chronic low back pain. Key highlights include an anticipated interim readout from the CLARITY trial and a $2.5 million share repurchase program. The presentation will be hosted by Executive Chairman Jeff Thramann.
Read more →-ACON
Jun 9, 2026Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform
Aclarion has partnered with PRIA Healthcare to enhance the reimbursement and commercial adoption of its AI-powered Nociscan platform for chronic low back pain. This Market Access Program aims to replicate the success of reimbursement wins in the UK, facilitating patient access and supporting healthcare providers in assessing the platform's clinical value. The collaboration is expected to streamline the reimbursement process and generate insights into payer dynamics.
Read more →-ACON
Jun 3, 2026Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
Aclarion, Inc. has partnered with the Institute of Neuro Innovation to enhance the availability of its Nociscan platform in the Los Angeles area. This collaboration aims to generate real-world evidence by comparing Nociscan's chemical biomarker data with SPECT-CT bone metabolic information. The partnership supports Aclarion's growth strategy while providing critical insights for treating chronic low back pain.
Read more →-ACON
Apr 30, 2026Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
Aclarion, Inc. reported a strong Q1 2026 with a 196% increase in Nociscan scan volumes, indicating accelerated adoption. The company is advancing its reimbursement strategies and has a robust financial position with no debt. Aclarion anticipates significant market opportunities as it integrates Nociscan into clinical workflows and prepares for upcoming clinical trial readouts.
Read more →-ACON
Apr 28, 2026Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
Aclarion, Inc. has appointed Daniel Keefe as the Commercial Director for the Western U.S. to enhance the adoption of its Nociscan technology. This move comes amid a significant increase in demand and utilization of Nociscan, which helps identify chronic low back pain sources. Keefe's extensive experience in the medical device industry is expected to bolster Aclarion's market presence.
Read more →-ACON
Apr 23, 2026Aclarion Announces $2.5 Million Stock Repurchase Plan
Aclarion, Inc. has announced a $2.5 million stock repurchase plan aimed at enhancing shareholder value while supporting the adoption of its Nociscan platform. The program will be executed over the next 12 months, depending on market conditions. Aclarion believes its current valuation does not fully reflect its growth potential, and the repurchase will be funded using existing cash reserves.
Read more →-ACON
Feb 5, 2026Aclarion Publishes 2026 Shareholder Letter from the Chairman
Aclarion, Inc. has released its 2026 Shareholder Letter, highlighting significant clinical and financial priorities. The company is set to report initial results from its 300-patient CLARITY trial by the end of Q3 2026. With a robust cash position extending into 2028, Aclarion aims to enhance shareholder value while advancing its innovative Nociscan technology for chronic low back pain.
Read more →-ACON
Feb 3, 2026Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation
Aclarion, Inc. has partnered with Source Healthcare to enhance the use of its Nociscan technology for chronic low back pain. This collaboration aims to fill a gap in pain management by providing real-world evidence comparing Nociscan with traditional anesthetic discography. Nociscan is a non-invasive tool that measures biomarkers related to spinal disc pain, showing promise in improving patient outcomes.
Read more →-ACON
Jan 13, 2026Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
Aclarion, Inc. has successfully closed a $10.4 million financing round, significantly enhancing its financial stability and extending its operational runway into 2028. This capital raise will support the commercialization of its Nociscan technology, which aims to improve the diagnosis of chronic low back pain. The company is now positioned for long-term growth and strategic partnerships.
Read more →Competitive Position
How ACON ranks across every disease it competes inCompetitive Position is a premium feature
See how ACON ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial